{"id":990039,"date":"2026-08-05T07:23:11","date_gmt":"2026-08-05T11:23:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/seres-therapeutics-reports-second-quarter-2026-financial-results-and-provides-business-updates-including-further-action-to-reduce-ongoing-facilities-costs\/"},"modified":"2026-08-05T07:23:11","modified_gmt":"2026-08-05T11:23:11","slug":"seres-therapeutics-reports-second-quarter-2026-financial-results-and-provides-business-updates-including-further-action-to-reduce-ongoing-facilities-costs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/seres-therapeutics-reports-second-quarter-2026-financial-results-and-provides-business-updates-including-further-action-to-reduce-ongoing-facilities-costs\/","title":{"rendered":"Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs"},"content":{"rendered":"
\n

\n Recently announced 80% of SER-155 recipients achieved immunosuppressive-free clinical response at day 15 for immune checkpoint inhibitor-related enterocolitis (irEC) in the investigator-sponsored trial (IST) conducted by Memorial Sloan Kettering Cancer Center (MSK)<\/em>\n <\/p>\n

\n IST data support SER-155 as a potential treatment for irEC that may allow patients to continue cancer therapy; Company evaluating irEC clinical development strategy in consultation with KOLs<\/em>\n <\/p>\n

\n Seres engaging potential partners, seeking capital to advance its SER-155 programs, including for the prevention of bloodstream infections in patients undergoing allo-HCT and those experiencing irEC <\/em>\n <\/p>\n

\n Seres announces agreement to exit additional leased space early, further reducing ongoing facility-related cash costs, which follows announcement of balance sheet strengthening and facilities cost reduction transactions in June 2026 <\/em>\n <\/p>\n

CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) — Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported second quarter 2026 financial results and provided business updates.<\/p>\n

“We are very pleased with the recent progress at Seres, including the positive topline data from the investigator-sponsored trial of SER-155 in irEC conducted by MSK, announced last month,” said Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres. “The study demonstrated that 80% of participants achieved an immunosuppressive-free clinical response at day 15, and the accompanying pharmacology data reinforced that our live biotherapeutic operated as designed, including by repairing the mucosal epithelial barrier. SER-155 to treat irEC, a frequent and often severe side effect of widely used immune checkpoint inhibitor (ICI) cancer treatment, represents a meaningful therapeutic and commercial opportunity, as many patients who experience irEC are required to halt their ICI therapy and begin immunosuppressive corticosteroid treatment. We are engaging potential partners, including companies with ICI franchises, as we evaluate the clinical development pathway in this indication and consider sources of financing. In parallel, we continue to pursue partnerships and other financing sources to support development of SER-155 in allo-HCT, and to advance our broader inflammatory and immune portfolio, including SER-603 for inflammatory bowel disease.”<\/p>\n

Marella Thorell, Chief Financial Officer of Seres, added, “Terminating our Sidney Street lease will substantially reduce our future lease obligations and will further lower our ongoing annual fixed costs beginning in 2027. Together with the lease restructuring we announced in June, this transaction reflects our continued focus on rigorous financial discipline, while we maintain the operational infrastructure needed to advance our live biotherapeutic pipeline, including our Phase 2-ready SER-155 program in allo-HCT.”<\/p>\n

\n Recent Highlights<\/strong>\n <\/p>\n

\n SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC)<\/strong>\n <\/p>\n